cyrilzakka/clinical-trials huggingface dataset:
Web Based Intervention to Reduce Weight Bias Among Dietitians

Weight bias in dietitians is prevalent and may affect patient care. The investigators conducted a randomized controlled trial to test if explicit and implicit bias could be influenced by a short, 20 minute educational video.

This randomized controlled trial studied the effect of three different videos on weight bias in a nationally representative sample of dietitians. The "intervention" group (I) watched a video about the etiology of obesity, reasons for weight regain, and how to talk to patients about weight. The first "control" group (C1) received information about the role of the environment and individual behavior in weight gain, and tools to help patients control their weight. The second control group (C2) received a weight neutral video about the role of dieticians in society. Bias measures were taken before and just after watching the video, and again one month later.

Eligibility Criteria:
Inclusion Criteria:

* Any dietitian in the Clinical Dietitian Registry Database.

Exclusion Criteria:

* None
Effect of Aerobics and Balancing Exercises on Anxiety and Dizziness in Patients With COVID-19

The recently emerged coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) is the newest threat to human health. It has already infected more than half a million people worldwide, leading to a lot of deaths. Patients with Coronavirus Disease 2019(COVID-19) will experience high levels of anxiety and low sleep quality due to isolation treatment. Purposes: Was to investigate the effect of aerobics and balancing exercises on anxiety and dizziness in patients with COVID-19. Subjects: Thirty anxiety and dizziness patients with COVID-19 aged from 45-65 years of both sexes, randomly divided into two groups, selected from outpatient clinic ,General

In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China, with clinical presentations greatly resembling viral pneumonia. Deep sequencing analysis from lower respiratory tract samples indicated a novel coronavirus, which was named 2019 novel coronavirus Disease (COVID-19). On February 12, 2020, WHO officially named the disease caused by the novel coronavirus as Coronavirus Disease 2019 (COVID-19),and by March 11th, 2020 when the number of countries involved was 114, with more than 118,000 cases and over 4000 deaths, the WHO declared the pandemic status

Eligibility Criteria:
Inclusion Criteria:

* Thirty patients with COVID-19
* Age between 45 -65 years
* Cooperative patient.
* All patients were referred from physician with the diagnosis of COVID-19

Exclusion Criteria:

* Overweigh patients with body mass index more than 30.
* Pregnant women.
* Cancer patients.
* Smokers
* Patients with chronic heart disease
Progressive Muscle Relaxation Exercises on Pain, Kinesiophobia and Functional Status

Relaxation techniques are a non-pharmacological therapy option applied to alleviate the symptoms of many different chronic diseases. It has been reported in the literature that PMR is effective on pain, fatigue and stress symptoms in fibromyalgia patients. No study has been found examining the effect of PMR on kinesiophobia and functional status in FM. This study was planned to examine the effect of progressive muscle relaxation exercises on pain, kinesiophobia and functional status in fibromyalgia patients.

Fibromyalgia (FM), which is a chronic pain disorder, is a difficult disease to treat, and it is stated that a multidisciplinary approach is required in its treatment rather than a single treatment method. Approaches that consider optimal symptom management and functional status in treatment, include non-pharmacological methods in addition to pharmacological treatment, and include psychosocial and behavioral methods are recommended. Non-pharmacological methods that have proven their effectiveness in FM treatment include aerobic exercise, patient education, cognitive therapies, balneotherapy, and physical therapy agents. One of the methods that can be applied in patients with FM is progressive muscle relaxation (PMR) exercises. PMR is an easy, low-cost, and side-effect-free relaxation technique. PMR helps individuals feel calmer and more relaxed through sequential muscle tension and relaxation. It has been reported in the literature that PMR is effective on pain, fatigue and stress symptoms in fibromyalgia patients. No study has been found examining the effect of PMR on kinesiophobia and functional status in FM. Therefore, this study was planned to examine the effect of progressive muscle relaxation exercises on pain, kinesiophobia and functional status in fibromyalgia patients.

Eligibility Criteria:
Inclusion Criteria:

* Being older than 18 years of age
* Having been diagnosed with fibromiyalgia for at least 6 months ago.
* Having no mental disability

Exclusion Criteria:

* Individuals receiving another complementary and integrative treatment
* Individuals who have done progressive muscle relaxation exercise before.
Lovaza Mechanisms of Action

High levels of triglycerides is a common abnormality found in patients with diabetes and also cardiovascular disease, and may contribute to the risk for both. Omega 3 fatty acids, as found enriched in fish and also in the commercial agent called Lovaza lower triglyceride levels. Prior work from the investigators group demonstrated that an enzyme responsible for the break down of triglycerides - lipoprotein lipase - generates molecules that can activate a specific nuclear receptor known as PPAR-alpha. This study investigates the hypothesis that taking Lovaza shifts the specific fatty acid content of triglyceride containing lipoproteins and increases the ability of those lipoproteins to activate PPAR-alpha.

This study will investigate changes in lipid and other metabolic parameters as well as the ability of isolated lipoproteins to activate PPARs in the presence or absence of lipoprotein lipase in a cohort of normal healthy individuals with modest hypertriglyceridemia before and after a course of Lovaza.

Eligibility Criteria:
Inclusion Criteria:

* Otherwise healthy 21 to 65 year old men and women
* Triglycerides \>150 \< 500 mg/dL

Exclusion Criteria:

* Other lipid lowering medication including fish oil
* Major illnesses
* Diabetes
* Cardiovascular disease
* Abnormalities uncovered on screening blood work including undiagnosed diabetes, abnormal liver function tests, triglycerides \> 500 mg/dL
* Indication for immediate statin therapy
* Pregnancy
* Contraindication for fish oil use or muscle biopsy
Spread Analysis of COVID-19 Outbreak in France by Self-assessment Web-application

A coronavirus pandemic began on 12/31/2019 with a first Chinese patient. As of 04/04/2020, the epidemic affects more than 190 countries with more than 50 million official contaminations and 1,251,000 deaths. (Univ J Hopkins). This virus causes a pathology ranging from simple flu-like symptoms in 80% of cases to acute respiratory distress syndromes requiring intensive care in 5% of cases and a death rate of 1.4 to 4% of cases.

Viral contamination is airborne and fecal A first epidemic wave crossed France in March / April 2020 then a second in October / November with a source of contamination which began in mid-August 2020. The sources of propagation are not well known (what places, what times, what contacts...? ) In the context of the health crisis linked to the coronavirus, knowledge of the sources of propagation of this 2nd wave is an important issue to guide end of lockdown and second lockdown policies.


Eligibility Criteria:
Inclusion criteria:

* users of the application
* not having objected to the use of their data

Exclusion criteria:

- user who does not have a complete questionnaire
Fontan Imaging Biomarkers (FIB) Study

The goal of the Fontan Imaging Biomarkers (FIB) study is to identify the associations of blood and urine biomarkers to imaging parameters of ventricular mechanics.

This study has the following research questions:

1. What is the reproducibility of ventricular systolic function measurements (including ventricular strain) in Fontan patients using echocardiography (Echo) and cardiac magnetic resonance imaging (CMR)?
2. What is the reproducibility of ventricular diastolic function measurements (including tissue Doppler and strain rate) in Fontan patients using Echo and CMR?
3. Is there a correlation between ventricular function measurements and circulating biomarkers (including galectin-3 levels, NT-proBNP, ST2, and MELD-XI score)?

Eligibility Criteria:
Inclusion Criteria:

* All patients with Fontan circulation undergoing clinically indicated CMR at Boston Children's Hospital will be considered for the study

Exclusion Criteria:

* Inadequate imaging quality to perform proposed analysis
* Patients \<15 kg will be excluded to simplify compliance with BCH minimal risk research blood draw volume guidelines (minimal risk is defined as \< 5% total blood volume)
Early Recanalization After Intravenous Thrombolysis with Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes

The purpose of this monocentric retrospective study is to compare, in patients with acute distal vessel occlusion stroke, the early rates of successful recanalization in patients treated with Alteplase (ALT) versus Tenecteplase (TNK), based on a retrospective analysis of magnetic resonance imaging (MRI) performed early after IVT.

Early rates of successful recanalization (SR) of distal vessel occlusions (DVO) following intravenous thrombolysis (IVT) between alteplase (ALT) and tenecteplase (TNK) are poorly known.

From March 2016 to February 2020, consecutive stroke patients hospitalized in the stroke unit of the Sud-Francilien Hospital with DVO identified on baseline MRI and suitable for IVT but not for mechanical thrombectomy will be included. In our stroke unit, patients were treated with ALT, 0.9 mg/kg from March 2016 to February 2018 and then with TNK, 0.25 mg/kg from March 2018 to December 2023. MRI was controlled 1-2 hours within IVT (MRI-2). Early recanalization was assessed on an adapted Arterial Occlusion Lesion (AOL) scale, SR being defined as AOL 2/3 scores on MRI-2. The rate reduction of thrombus length (TL) when thrombus persisted, the IVT response threshold of TL and the infarct size evolution were also assessed. In the present study, the investigators sought to compare early rates of SR between the two lytics, based on a retrospective analysis of magnetic resonance imaging (MRI) performed early after IVT.

Eligibility Criteria:
Inclusion Criteria:

* Age≥ 18 years.
* Acute ischemic stroke (visible on DWI, but not visible on FLAIR) on initial MRI associated with distal arterial occlusion as defined below:

  * A distal occlusion of the M2 segment of the middle cerebral artery (MCA)
  * Occlusion (regardless of location) of a non-dominant M2 branch of the MCA
  * Occlusion of the M3 segment of the MCA.
  * Occlusion of the A2 or A3 segment of the anterior cerebral artery (ACA)
  * Occlusion of the P2 or P3 branch of the posterior cerebral artery (PCA).
  * A proximal M2-MCA or proximal P1-PCA occlusion may also be included if not eligible for mechanical thrombectomy, especially if the initial NIHSS score is low (\<5).
  * Distal arterial occlusion is identified by MRI either on the TOF (Time of Flight)-ARM sequence and/or on the presence of a thrombus (Susceptibility Vessel sign, SVS) on the SWAN sequence,
* IVT by ALT or TNK within 4H30 after onset of symptoms,
* Early brain MRI performed 1 to 2 hours after IVT (MRI n°2),
* Good quality MRI (absence of motion artifact interfering with interpretation) with availability of DWI, FLAIR, TOF-MRA and SWAN sequences.

Exclusion Criteria:

- Patients informed of the study who objected to the collection of their data.
A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants

The purpose of this study is to determine the effects of Activamp, a product containing gynostemma pentaphyllum extract, on body weight, fat loss and metabolic markers in healthy overweight adults.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male or female 21-55 years of age
* BMI of 25.0 kg/m2 to 29.9 kg/m2 (± 1.0kg/m2)
* Must have negative urine pregnancy test at screening
* Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
* Subject agrees to maintain their normal level of physical activity throughout the study
* Weight has been stable for the last 3 months
* Subject agrees to comply with study procedures
* Healthy as determined by laboratory results, medical history and physical exam
* Subject agrees not to participate in structured activity including resistance training and aerobic exercise more than 3 times per week
* Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

* Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
* Subject who have experienced a greater than 10% variation in body weight in the past 3 months
* History of, or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems
* History of surgery for weight loss (including gastric bypass or lapband)
* History of conditions that could interfere with the test product or impede its absorption such as gastrointestinal disease (Crohn's disease) or experienced surgery (caecum or enterocele surgery)
* Subjects diagnosed with Type II Diabetes
* Subjects with active cancer (excluding basal cell carcinoma)
* Subjects with active eating disorders
* Subjects who have undergone anti-psychotic drug therapy within the past 2 months
* Use of prescription or over the counter medications known to affect weight within 3 weeks of randomization or during the study
* Use of any supplements, programs, or meal replacement products, other than those provided, intended to alter body weight within two weeks of screening or during the course of the study
* Use of illicit drugs or history of drug or alcohol abuse within the past 6 months
* Currently having more than 2 standard alcoholic drinks per day
* Participation in a clinical research trial within 30 days prior to randomization
* Allergy or sensitivity to test article ingredients
* Individuals who are cognitively impaired and/or who are unable to give informed consent
* Abnormal lab test results or any other medical or psychological condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
Adolescent Nutrition in Girls in Burkina Faso and Ethiopia

Adolescents' diets are key to breaking the intergenerational cycle of malnutrition. This study will guide policies and programs on the adequacy, acceptability, and feasibility of implementing balanced energy protein and multiple micronutrient supplementations to fill nutrient gaps in adolescent girls. Using a trial, the study will assess dietary intake and nutrient gaps, acceptability of balanced energy protein and multiple micronutrient supplementations. In addition to the trial, the study will the assess willingness to pay for the supplements and the most effective delivery platform and model to reach vulnerable adolescent girls. The most effective delivery platform and model to reach vulnerable adolescent girls cost-effectively will also be assessed through interviews with (inter)national experts, producers, and the donor community.

In low- and middle-income countries, it is estimated that each year, 21 million adolescent girls become mothers. Infants of adolescent mothers are at increased risk of delivering babies preterm, with low birth weight or length. Targeting nutrition interventions to improve adolescent girls' diet and nutrition is crucial to breaking the intergenerational cycle of poor growth and development. There is a specific need to assess how a balanced energy protein (BEP) and multiple micronutrient (MMN) supplement interventions can be tailored to adolescent girls and women of reproductive age.

This study aims to assess the adequacy, acceptability, and feasibility of implementing nutritional supplementations to fill nutrient gaps in adolescent girls in resource-limited settings. A trial will specifically:

1. assess the short-term acceptability of BEP and MMN supplements
2. assess how nutrition supplements increase nutrient adequacy of diets adolescent girls in resources-limited settings;

Using a qualitative component, the study explores the food agency of adolescents and the most effective delivery platform to reach vulnerable adolescent girls cost-effectively. The overall aim is to guide policies and programs on new formulations of nutritional supplements for adolescent girls in resource-limited settings.

Eligibility Criteria:
Eligibility criteria are all based on self-reported information

Inclusion criteria:

* Non-pregnant and non-lactating women
* Without any known chronic illness or acute illness affecting appetite
* Permanent residents of the study area

Exclusion criteria:

* Being allergic to peanuts
* Eating disorders or dietary restrictions
Effect of N-Acetylcysteine (NAC) on Creatinine in Chronic Kidney Disease

N-acetylcysteine is used to reduce the risk of injury to the kidney after the administration of contrast dye. The mechanism and effectiveness of this intervention is not substantiated in the literature. The investigators hypothesize that serum creatinine will be lower in patients who receive NAC compared to those who receive the placebo but serum cystatin C will not change in patients who receive NAC compared to those who receive the placebo. Also urine creatinine will increase after the administration of NAC compared to before the administration of NAC.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with an eGFR between 30-60 ml/min calculated using last available creatinine and patient weight.
2. Age \> 18
3. No known allergies to or adverse effects from NAC
4. No known scheduled radio-contrast procedures
5. No medications known to affect creatinine secretion
Effects of Mineralocorticoid Receptor Stimulation on Cognition

In this study the effects of mineralocorticoid stimulation on social cognition will be investigated in healthy young individuals.

80 healthy young individuals (40 females and 40 male) will be recruited an randomized to either placebo or 0.4 mg Fludrocortison before testing. Tasks will on emotion recognition, Task Switch, visual spacial memory and decision making will be conducted.

Eligibility Criteria:
Inclusion Criteria:

* free of medication
* age 18 - 30

Exclusion Criteria:

* any medication
* severe illness
Analgesic Efficacy of Nefopam in Patients Undergoing Kidney Transplantation

The investigators examined the efficacy of nefopam in patients undergoing kidney transplantation.

Drug combination are frequently used to relieve postoperative pain. Nefopam can inhibit serotonin, dopamine, and norepinephrine reuptake through central mechanisms. Several studies have demonstrated analgesic efficacy of nefopam in the postoperative period. The purpose of this study is to ascertain the analgesic effect and tolerance of intravenous nefopam in combination with fentanyl based patient-controlled analgesia after kidney transplantation.

Eligibility Criteria:
Inclusion Criteria:

* elective living donor kidney transplantation

Exclusion Criteria:

* pre-operative tachycardia (\> 100bpm)
* liver dysfunction
* severe cardiac disease
* body mass index ≥ 30 kg/m2
* drug allergy
ItAlian ReGistry of PNeumoniA in ImmUnocompromised PaTients (ARGONAUT)

This multicentric, prospective study aims at:

evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.

Primary endpoint:

Collection of in- hospitalisation mortality for all causes in immunocompromised patients with CAP enrolled.

Secondary endpoints:

Collection of data on admission and during hospitalisation to evaluate clinical response to empirical treatments (including antibiotic therapy) related to severity of disease and microbiological etiology.

Prevalence of cardiovascular events and all-cause mortality during hospitalization or after discharge.

Biochemical, microbiological and genetic analysis on collected samples.

Eligibility Criteria:
Inclusion Criteria:

Hospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression:

* AIDS,
* Aplastic anemia;
* Asplenia;
* Hematologic malignancy (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma);
* Chemotherapy within the last 3 months;
* Neutropenia defined as a white blood cell count less than 500/dL on a complete blood count;
* Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;
* Solid organ transplant;
* Bone marrow transplant;
* Chronic oral steroid use (\>10 mg/day prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose \> 600 mg prednisone);
* Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose \> 600 mg prednisone;
* Active malignancy;
* Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);
* Lung malignancy with neutropenia/chemotherapy;
* Other solid malignancy with neutropenia/chemotherapy;
* Other immunodeficiency (including congenital/genetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);
* Primary immunodeficiency.

Exclusion Criteria:

* None